natgillin/translations-raw huggingface dataset:
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulinInsulin Human Winthrop je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
40 Transfer to Insulin Human Winthrop Rapid
Prehod na Insulin Human Winthrop Rapid
Insulin Human Winthrop Rapid in cartridges for OptiClik has been developed for use with OptiClik only.
Insulin Human Winthrop Rapid v vložkih za injekcijski peresnik OptiClik je pripravljen samo za uporabo v injekcijskih peresnikih OptiClik.
41 4.4 Special warnings and precautions for use
39 4. 4 Posebna opozorila in previdnostni ukrepi
42 Adherence of the patient to the dosage and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia.
Za zmanjšanje nevarnosti hipoglikemije mora bolnik nujno upoštevati shemo odmerjanja in načrt prehrane, pravilno aplicirati insulin in poznati simptome hipoglikemije.
43 Lactation
Dojenje
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment.
41 Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije, pa tudi npr. zaradi prizadetosti vida.
44 Eyes disorders
Očesne bolezni
Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
42 Dolgoročno izboljšanje glikemične urejenosti zmanjša nevarnost za napredovanje diabetične retinopatije.
45 Mode of action
Način delovanja
Pharmacodynamic characteristics
43 Farmakodinamične značilnosti
Keep the cartridge in the outer carton in order to protect from light.
44 Vložek shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
For storage precautions, see section 6.3.
Vložki, ki jih uporabljate Za navodila za shranjevanje glejte poglavje 6. 3.
3 ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
Insulin pen The cartridges for OptiClik are to be used in conjunction OptiClik only and as recommended in the information provided by the device manufacturer.
Vložki za injekcijski peresnik OptiClik se uporabljajo samo skupaj z injekcijskim peresnikom OptiClik in po navodilih izdelovalca injekcijskega peresnika.
47 Mixing of insulins
Mešanje insulinov
Insulin Human Winthrop Rapid cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
Vložki Insulin Human Winthrop Rapid za injekcijski peresnik OptiClik niso zasnovani tako, da bi dovoljevali mešanje kakšnega drugega insulina v vložku za injekcijski peresnik OptiClik.
Clear, colourless solution of water-like consistency.
Raztopina je bistra, brezbarvna, vodi podobne konsistence.
49 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
47 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
50 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
48 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
51 Handling of the pen
49 Ravnanje z injekcijskim peresnikom
SoloStar has to be used as recommended in these Instructions for Use (see section 6.6).
SoloStar uporabljajte kot je priporočeno v navodilih za ravnanje s SoloStarjem (glejte poglavje 6. 6).
52 4.8 Undesirable effects
50 4. 8 Neželeni učinki
53 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
51 Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
54 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
In healthy subjects, the serum half-life of insulin is approximately 4 to 6 minutes.
52 Pri zdravih osebah je razpolovni čas insulina v serumu približno 4 do 6 minut.
Store in a refrigerator (2°C - 8°C).
Injekcijski peresniki, ki jih ne uporabljate Shranjujte v hladilniku (2 °C - 8 °C).
55 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml solution in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
53 3 ml raztopina v vložku (iz brezbarvnega stekla tipa 1), z batom (iz brombutilne gume (tipa 1)) ter s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
56 Handling of the pen
pokrovček peresnika
The Instructions for Use included in the Package Leaflet must be read carefully before using SoloStar.
igla peresnika (ni priložena)
Schematic diagram of the pen
insulinski rezervoar
Important information for use of SoloStar:
Shematični prikaz injekcijskega peresnika
• Before each use, a new needle must always be carefully attached and a safety test must be performed.
Pomembne informacije za uporabo SoloStarja: • Pred vsako uporabo morate natančno namestiti novo iglo in opraviti varnostni preizkus.
Only use needles that are compatible for use with SoloStar. • Special caution must be taken to avoid accidental needle injury and transmission of infection. • Never use SoloStar if it is damaged or if you are not sure that it is working properly. • Always have a spare SoloStar in case your SoloStar is lost or damaged.
Uporabljajte le igle, primerne za uporabo s SoloStarjem. • Posebej morate paziti, da boste preprečili naključne poškodbe z iglo in prenos okužbe. • Ne uporabljajte SoloStarja, če je poškodovan ali če niste prepričani, da deluje pravilno. • Vedno imejte na zalogi rezervni SoloStar, če injekcijski peresnik izgubite ali se poškoduje.
If SoloStar is in cool storage, it should be taken out 1 to 2 hours before injection to allow it to warm up.
Če je SoloStar shranjen na hladnem, ga morate vzeti iz hladilnika 1 do 2 uri pred injiciranjem, da se ogreje.
The label on the pen should be checked to make sure it contains the correct insulin.
Preveriti je treba napis na injekcijskem peresniku, da se prepričate, če vsebuje pravi insulin.
After removing the pen cap, the appearance of the insulin should also be checked: • The insulin solution (Insulin Human Winthrop Rapid) must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Po odstranitvi pokrovčka injekcijskega peresnika je treba preveriti videz insulina: • Raztopina insulina (Insulin Human Winthrop Rapid) mora biti bistra, brezbarvna, brez vidnih trdnih delcev in vodi podobne konsistence.
Do not use this SoloStar if insulin is cloudy, coloured or has particles. • The insulin suspensions (Insulin Human Winthrop Basal or Insulin Human Winthrop mixtures) should be mixed by turning SoloStar up and down at least 10 times to resuspend the insulin.
Ne uporabite SoloStarja, če je insulin moten, obaravan ali so v njem delci. • Suspenzije insulina (Insulin Human Winthrop Basal ali mešanice zdravila Insulin Human Winthrop) pretresite z obračanjem SoloStarja gor in dol vsaj 10- krat, tako da insulin ponovno suspendirate.
The pen should be turned gently to avoid foaming in the cartridge.
Injekcijski peresnik obračajte nežno, da se izognete penjenju v vložku.
57 Step 2.
55 Korak 2.
Prior to each injection, a safety test has to be performed to ensure that pen and needle work properly and to remove air bubbles.
injiciranjem morate opraviti varnostni preizkus, s katerim se prepričate, da injekcijski igla pravilno delujeta, in odstranite zračne mehurčke.
Select a dose of 2 units.
Nastavite odmerek 2 enoti.
If you need a dose greater than 80 units, you should give it as two or more injections.
Če je potrebni odmerek večji od 80 enot, ga je treba dati z dvema ali več injiciranji.
Inject the dose
Napolnite odmerek
The needle should be inserted into the skin.
Iglo morate zabosti v kožo.
Then the injection button should be held down 10 seconds before withdrawing the needle.
Preden iglo potegnete iz kože, morate gumb za injiciranje držati pritisnjen 10 sekund.
Remove and discard the needle
Injicirajte odmerek
Needles mut not be reused.
Igel ne smete ponovno uporabiti.
Special caution must be taken when removing and disposing of the needle.
Posebna previdnost je potrebna, ko iglo odstranjujete in zavržete.
EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
56 EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX EU/ 1/ 06/ 368/ XXX
59 1.
57 1.
Insulin Human Winthrop Basal 100 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Basal 100 i. e. / ml suspenzija za injiciranje v viali
Each vial contains 5 ml of suspension for injection, equivalent to 500 IU insulin.
Vsaka viala vsebuje 5 ml suspenzije za injiciranje, kar ustreza 500 i. e. insulina.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin vInsulin Human Winthropje pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
After re-suspension, milky white suspension.
Po ponovnem suspendiranju je suspenzija mlečno bela.
60 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
58 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Basal contains 100 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Basal vsebuje 100 i. e. insulina.
61 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
59 Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
62 Intercurrent illness
Sočasne bolezni
4.5 Interaction with other medicinal products and other forms of interaction
60 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Insulin Human Winthrop Basal can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Basal je med dojenjem dovoljeno uporabljati.
63 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
Bolnikom je treba svetovati, naj upoštevajo ustrezne varnostne ukrepe, da bi se izognili hipoglikemiji med upravljanjem vozila.
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
61 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
64 Skin and subcutaneous tissue disorders
Bolezni kože in podkožja
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
62 Občasni: urtikarija na mestu injiciranja Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
Insulins and analogues, intermediate-acting, ATC Code:
Insulini s srednje dolgim delovanjem in analogi, oznaka ATC:
65 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
The acute toxicity was studied following subcutaneous administration in rats.
63 Akutno toksičnost so proučili po subkutani uporabi pri podganah.
The product may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi viale Zdravilo lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
For storage precautions, see section 6.3.
Odprte viale Za navodila za shranjevanje glejte poglavje 6. 3.
66 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
6.6 Special precautions for disposal and other handling
64 6. 6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re- suspended.
Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Insulin Human Winthrop Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulina Insulin Human Winthrop Basal se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno viale.
As with all insulin preparations, Insulin Human Winthrop Basal must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Tako kot velja za vse pripravke insulinov, tudi zdravila Insulin Human Winthrop Basal ne smete mešati z raztopinami, ki vsebujejo reducente, npr. tiole ali sulfite.
It must also be remembered that insulin protamine crystals dissolve in an acid pH range.
Zavedati se je treba, da se kristali insulin protamina raztapljajo v kislem pH območju.
Insulin Human Winthrop Basal may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Basal se sme mešati z vsemi humanimi insulini, ki jih izdeluje Sanofi - Aventis, NE pa s tistimi, ki so posebej pripravljeni za uporabo v insulinskih črpalkah.
Insulin Human Winthrop Basal must also NOT be mixed with insulins of animal origin or with insulin analogues.
Zdravila Insulin Human Winthrop Basal prav tako NE smete mešati z insulini živalskega izvora ali insulinskimi analogi.
68 1.
65 1.
Insulin Human Winthrop Basal 40 IU/ ml suspension for injection in a vial
Insulin Human Winthrop Basal 40 i. e. / ml suspenzija za injiciranje v viali
Each ml contains 40 IU insulin human (equivalent to 1.4 mg).
En mililiter vsebuje 40 i. e. humanega insulina (kar ustreza 1, 4 mg).
Each vial contains 10 ml of suspension for injection, equivalent to 400 IU insulin.
Vsaka viala vsebuje 10 ml suspenzije za injiciranje, kar ustreza 400 i. e. insulina.
69 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Basal contains 40 IU of insulin per ml suspension.
En mililiter suspenzije Insulin Human Winthrop Basal vsebuje 40 i. e. insulina.
Fur further details on handling, see section 6.6.
Za podrobnosti o ravnanju z zdravilom glejte poglavje 6. 6.
70 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
Pri bolnikih z okvaro ledvic se lahko potreba po insulinu zaradi zmanjšane presnove insulina zmanjša.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
67 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
71 Intercurrent illness
Sočasne bolezni
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
68 Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka humanega insulina.
Insulin Human Winthrop Basal can be used during breastfeeding.
Zdravilo Insulin Human Winthrop Rapid je med dojenjem dovoljeno uporabljati.
72 4.8 Undesirable effects
4. 8 Neželeni učinki
Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
69 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
73 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
Tako kot pri zdravljenju z vsakim insulinom se lahko na mestu injiciranja pojavi lipodistrofija, ki upočasni lokalno absorpcijo insulina.
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
70 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
74 5.2 Pharmacokinetic properties
5. 2 Farmakokinetične lastnosti
Immediately before withdrawal from the vial into the injection syringe, the insulin must be re- suspended.
72 Tik pred izvlekom iz viale v injekcijsko brizgo je treba insulin ponovno suspendirati.
Insulin Human Winthrop Basal 100 IU/ ml suspension for injection in a cartridge
Insulin Human Winthrop Basal 100 i. e. / ml suspenzija za injiciranje v vložku
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter vsebuje 100 i. e. humanega insulina
Each cartridge contains 3 ml of suspension for injection, equivalent to 300 IU insulin.
Vsak vložek vsebuje 3 ml suspenzije za injiciranje, kar ustreza 300 i. e. insulina.
78 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
74 Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
Insulin Human Winthrop Basal in cartridges has been developed for use in the OptiPen series.
Insulin Human Winthrop Basal v vložkih je pripravljen za uporabo v injekcijskih peresnikih OptiPen.
79 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Pri bolnikih s hudo okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
75 V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
80 4.5 Interaction with other medicinal products and other forms of interaction
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
76 Na presnovo glukoze vplivajo številna zdravila oz. snovi in potrebna utegne biti prilagoditev odmerka humanega insulina.
81 Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage.
77 Hude hipoglikemije lahko povzročijo nevrološke okvare, zlasti če se ponavljajo.
82 General disorders and administration site conditions
Splošne težave in spremembe na mestu aplikacije
Common: injection site reactions Uncommon: injection site urticaria Not known: injection site inflammation, injection site swelling, injection site pain, injection site pruritus, injection site erythema.
78 Ni znano: vnetje na mestu injiciranja, oteklost na mestu injiciranja, bolečina na mestu injiciranja, srbenje na mestu injiciranja, eritem na mestu injiciranja.
83 5.3 Preclinical safety data
5. 3 Predklinični podatki o varnosti
Protamine sulphate, metacresol, phenol, zinc chloride, sodium dihydrogen phosphate dihydrate, glycerol, sodium hydroxide, hydrochloric acid (for pH adjustment), water for injections.
Protaminijev sulfat, metakrezol, fenol, cinkov klorid, atrijev dihidrogenfosfat dihidrat, glicerol, natrijev hidroksid klorovodikova kislina (za uravnavanje pH), voda za injekcije.
The cartridge in-use (in the insulin pen) or carried as a spare may be stored for a maximum of 4 weeks not above 25°C away from direct heat or direct light.
Rok uporabnosti po prvi uporabi vložka Vložek, ki ga uporabljate ali ga imate pri sebi za rezervo lahko shranjujete največ 4 tedne pri temperaturi do 25 °C zaščiteno pred neposredno toploto ali svetlobo.
84 6.5 Nature and contents of container
6. 5 Vrsta ovojnine in vsebina
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
3 ml suspenzija v vložku (iz brezbarvnega stekla tipa 1) z batom (iz brombutilne gume (tipa 1)) in s prirobljeno zaporko (iz aluminija) z zamaškom (iz brombutilne ali laminata poliizoprenske in brombutilne gume (tipa 1)).
If the pen malfunctions (see instructions for using the pen), the suspension may be drawn from the cartridge into an injection syringe (suitable for an insulin with 100 IU/ ml) and injected.
Če se injekcijski peresnik pokvari (glejte navodila za uporabo injekcijskega peresnika), je mogoče suspenzijo potegniti iz vložka z injekcijsko brizgo (primerno za insulin s 100 i. e. / ml) in injicirati.
Cartridges Before insertion into the pen, Insulin Human Winthrop Basal must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Pred vstavitvijo v injekcijski peresnik mora biti Insulin Human Winthrop Basal 1 do 2 uri na sobni temperaturi, potem pa ga je treba za preverjanje vsebine ponovno suspendirati.
Insulin Human Winthrop Basal must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulina Insulin Human Winthrop Basal se ne sme uporabiti, če tega ni mogoče doseči – če suspenzija npr. ostane bistra, se v insulinu pojavijo grude, delci ali kosmi ali se lepijo na steno ali dno vložka.
85 Any unused product or waste material should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Insulin Human Winthrop Basal 100 IU/ ml suspension for injection in a pre-filled pen.
Insulin Human Winthrop Basal 100 i. e. / ml suspenzija za injiciranje v napolnjenem injekcijskem peresniku
Each pen contains 3 ml of suspension for injection, equivalent to 300 IU insulin.
Vsak injekcijski peresnik vsebuje 3 ml suspenzije za injiciranje, kar ustreza 300 i. e. insulina.
OptiSet.
Suspenzija za injiciranje v napolnjenem injekcijskem peresniku OptiSet.
OptiSet delivers insulin in increments of 2 IU up to a maximum single dose of 40 IU.
Z injekcijskem peresnikom Insulin Human WinthropOptiSet je mogoče odmerek nastavljati v stopnjah po 2 i. e. do največjega posamičnega odmerka 40 i. e.
87 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki